Antonia Vlahou
YOU?
Author Swipe
View article: Urinary peptidomic signatures predict overall and progression-free survival in patients with bladder cancer
Urinary peptidomic signatures predict overall and progression-free survival in patients with bladder cancer Open
Clinicopathologic calculators for bladder cancer moderately predict survival and fail to depict the underlying molecular phenotype. We applied urinary capillary electrophoresis–mass spectrometry (CE–MS) to identify prognostic signatures li…
View article: A proteomics resource investigating fibrosis: proof-of-concept for identifying novel drug candidates
A proteomics resource investigating fibrosis: proof-of-concept for identifying novel drug candidates Open
View article: Pan-fibrotic gene expression signature in major chronic diseases by integrative bulk and single-cell transcriptomic analyses
Pan-fibrotic gene expression signature in major chronic diseases by integrative bulk and single-cell transcriptomic analyses Open
Background Fibrosis is a common pathological endpoint across multiple chronic diseases affecting organs, including the liver, kidney, and heart. Despite its prevalence and clinical burden, there are currently no robust validated molecular …
View article: #1091 Progression of cardiac remodelling and dysfunction is accompanied by altered metabolic profile in chronic kidney disease
#1091 Progression of cardiac remodelling and dysfunction is accompanied by altered metabolic profile in chronic kidney disease Open
Background and Aims The heart and kidneys are vital organs that influence each other's function. Dysfunction in one inevitably leads to dysfunction in the other and is known as cardiorenal syndrome (CRS). CRS type 4 is defined by chronic k…
View article: In silico prediction of optimal multifactorial intervention in chronic kidney disease
In silico prediction of optimal multifactorial intervention in chronic kidney disease Open
Background Chronic kidney disease (CKD) contributes to global morbidity and mortality. Early, targeted intervention can help mitigate its impact. CK273 is a urinary peptide classifier previously validated in a prospective clinical trial fo…
View article: Comparative evaluation of imputation and batch-effect correction for proteomics/peptidomics differential-expression analysis
Comparative evaluation of imputation and batch-effect correction for proteomics/peptidomics differential-expression analysis Open
Mass spectrometry (MS)-based proteomics offers powerful opportunities for biomarker discovery; nevertheless, it is associated with technical challenges, some of them being missing values and batch effects. Both can obscure biological signa…
View article: A Naturally Occurring Urinary Collagen Type I Alpha 1-Derived Peptide Inhibits Collagen Type I-Induced Endothelial Cell Migration at Physiological Concentrations
A Naturally Occurring Urinary Collagen Type I Alpha 1-Derived Peptide Inhibits Collagen Type I-Induced Endothelial Cell Migration at Physiological Concentrations Open
Collagen type I (COL(I)) is a key component of the extracellular matrix (ECM) and is involved in cell signaling and migration through cell receptors. Collagen degradation produces bioactive peptides (matrikines), which influence cellular p…
View article: Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology Open
Prostate cancer accounts for approximately 1.5 million new diagnoses and 400,000 deaths every year worldwide, and demographic projections indicate a near-doubling of both figures by 2040. Despite existing treatments, 10–20% of patients eve…
View article: Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens
Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens Open
Multiple myeloma (MM) remains incurable; gaps in our understanding of MM molecular pathogenesis and drugs’ resistance mechanisms are involved in the failure of therapies. This study aims to identify proteins significantly impacting MM pati…
View article: Profiling Neoadjuvant Therapy Response in Rectal Cancer Using Publicly Available Transcriptomic RNA-seq Datasets
Profiling Neoadjuvant Therapy Response in Rectal Cancer Using Publicly Available Transcriptomic RNA-seq Datasets Open
Neoadjuvant chemoradiotherapy followed by total mesorectal excision is standard for locally advanced rectal cancer, but response varies and current markers are insufficient. This study integrates public bulk RNAseq data to identify predict…
View article: Simple, fast, and reliable analysis of label-free proteomics data with the Proteomics Eye (ProtE)
Simple, fast, and reliable analysis of label-free proteomics data with the Proteomics Eye (ProtE) Open
View article: A naturally occurring urinary collagen type I alpha 1-derived peptide inhibits collagen type I-induced endothelial cell migration at physiological concentrations
A naturally occurring urinary collagen type I alpha 1-derived peptide inhibits collagen type I-induced endothelial cell migration at physiological concentrations Open
Collagen type I (COL(I)) is a key component of the extracellular matrix (ECM) and is involved in cell signalling and migration through cell receptors. Collagen degradation produces bioactive peptides (matrikines), which influence cellular …
View article: A proteomics resource investigating fibrosis: proof-of-concept for identifying novel drug candidates
A proteomics resource investigating fibrosis: proof-of-concept for identifying novel drug candidates Open
View article: Urinary collagen peptides predict mortality
Urinary collagen peptides predict mortality Open
Background Organ fibrosis caused by the presence of excessive extracellular matrix (ECM) is strongly related to mortality. Urinary peptide signatures were reported predictive of death in SARS-CoV-2 and chronic kidney disease. Such signatur…
View article: Figure 6 from Repurposing Amiodarone for Bladder Cancer Treatment
Figure 6 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Amiodarone inhibits mTOR and MAPK pathways. Cells were treated for 24 hours with increasing concentrations of amiodarone (0, 12.5, and 25 μmol/L), and the expression of the proteins AKT, mTOR, S6, and p44/42 MAPK, both phosphorylated (p-) …
View article: Supplementary Table 2 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Table 2 from Repurposing Amiodarone for Bladder Cancer Treatment Open
List of differentially abundant proteins between muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC)
View article: Figure 4 from Repurposing Amiodarone for Bladder Cancer Treatment
Figure 4 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Amiodarone induces apoptosis in bladder cancer cell lines. Cells were treated for 48 or 72 hours with amiodarone (0, 25, and 50 μmol/L for UMUC3; 0, 12.5, and 25 μmol/L for HT1197, BFTC905, and RT112). A, Apoptosis was evaluated usi…
View article: Supplementary Figure 2 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Figure 2 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Supplementary Figure 2. The effect of amiodarone is bladder cancer specific. Real-time proliferation assays in the benign bladder cells HBLAK using the IncucyteS3 System. The cells were treated with increasing concentrations of amiodarone …
View article: Supplementary Table 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Table 1 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Differentially expressed genes (DEGs) between muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NBIMC).
View article: Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Development of molecular signature and CMap analysis. A, A molecular signature was established through the integration of significant changes between MIBC and NMIBC derived from multiomics data (proteomics and transcriptomics), furt…
View article: Figure 2 from Repurposing Amiodarone for Bladder Cancer Treatment
Figure 2 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Amiodarone decreases proliferation in bladder cancer cell lines. Real-time proliferation assays in UMUC3, HT1197, BFTC905, and RT112 were conducted using the Incucyte S3 system. The cells were treated with increasing concentrations of amio…
View article: Figure 3 from Repurposing Amiodarone for Bladder Cancer Treatment
Figure 3 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Amiodarone decreases colony formation capacity in bladder cancer cell lines. Cells seeded in six-well plates were treated with increasing concentrations of amiodarone (0–5 μmol/L). After incubation for 7 to 10 days, the cells were stained …
View article: Supplementary Figure Legends from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Figure Legends from Repurposing Amiodarone for Bladder Cancer Treatment Open
File contains 2 Supplementary Figure legends
View article: Figure 5 from Repurposing Amiodarone for Bladder Cancer Treatment
Figure 5 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Amiodarone reduces bladder cancer tumor growth in vivo. Tumor growth in BFTC905-bearing NOD/SCID mice treated with 75 mg/kg of amiodarone. A, Tumor volume over time in control (n = 6) and amiodarone-treated (n =…
View article: Supplementary File 2 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary File 2 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Gene expression results
View article: Supplementary File 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary File 1 from Repurposing Amiodarone for Bladder Cancer Treatment Open
The analysis based on the previously generated proteomics data
View article: Supplementary Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment
Supplementary Figure 1 from Repurposing Amiodarone for Bladder Cancer Treatment Open
Supplementary Figure 1. Fluvoxamine, amiodarone, isradipine, and amodiaquine reduce viability in BC cell lines. A, UMUC3, HT1197, BFTC905, and RT112 cells were treated for 96 h with increasing concentrations (0–100 μM) of fluvoxamine (A), …
View article: Data from Repurposing Amiodarone for Bladder Cancer Treatment
Data from Repurposing Amiodarone for Bladder Cancer Treatment Open
Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for new therapeutic strategies. Drug repurposing h…
View article: Repurposing Amiodarone for Bladder Cancer Treatment
Repurposing Amiodarone for Bladder Cancer Treatment Open
Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for new therapeutic strategies. Drug repurposing h…
View article: Redox Mechanisms Driving Skin Fibroblast-to-Myofibroblast Differentiation
Redox Mechanisms Driving Skin Fibroblast-to-Myofibroblast Differentiation Open
Transforming Growth Factor-Beta 1 (TGF-β1) plays a pivotal role in the differentiation of fibroblasts into myofibroblasts, which is a critical process in tissue repair, fibrosis, and wound healing. Upon exposure to TGF-β1, fibroblasts acqu…